重磅!又一款新分子抑制剂被纳入突破性药物品种

关键词
阿尔兹海默病 细胞免疫 免疫检查点 融合蛋白 基因变异 高通量测序 抗体偶联药物
#今日行业热点#
①Nature Communications:Functional variants identify sex-specific genes and pathways in Alzheimer's Disease
功能性变异体确定了阿尔茨海默病中的性别特异性基因和通路
DOI: 10.1038/s41467-023-38374-z
②Neuro-Oncology:Cell-based therapies for glioblastoma: Promising tools against tumor heterogeneity
综述:基于胶质母细胞瘤(GBM)的细胞免疫和干细胞开发策略:对抗肿瘤异质性的有前景的工具
DOI :10.1093/neuonc/noad092
③Cell子刊:Targeted Therapy for Rare Lung Cancers: Status, Challenges, and Prospects
综述:针对罕见肺癌的靶向基因改变和免疫检查点策略的现状、挑战与前景展望
DOI :10.1016/j.ymthe.2023.05.007
④Oncoimmunology:Novel Fab-peptide-HLA-I fusion proteins for redirecting pre-existing anti-CMV T cell immunity to selective eliminate carcinoma cells
新型重组Fab-peptide-HLA-I融合蛋白用于重新定向高度流行的抗病毒T细胞克隆以选择性消除癌细胞
DOI :10.1080/2162402X.2023.2207868
⑤Nature子刊:Immune gene variation associated with chromosome-scale differences among individual zebrafish genomes
与个体斑马鱼基因组染色体尺度差异相关的免疫基因变异
DOI: 10.1038/s41598-023-34467-3
⑥Journal of Ovarian Research:Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing
通过高通量测序鉴定A2780和A2780/DDP人卵巢癌细胞外泌体中上调的miRNA
DOI: 10.1186/s13048-023-01157-7
⑦高效口服新分子实体化合物KRASG12C抑制剂IBI351被国家药品监督管理局纳入突破性药物品种,用于晚期结直肠癌(Colorectal carcinoma, CRC)
⑧阿尔兹海默病激越药物依匹哌唑(Brexpiprazole)获FDA批准上市,这是FDA批准的首款也是唯一一款用于此类疾病的药物
⑨我国首个mRNA新冠疫苗在石家庄接种全国首针
⑩阿斯利康获得同类首创分子潜力的新型GPRC5D靶向抗体偶联药物LM-305全球独家授权协议,该ADC药物将聚焦于多发性骨髓瘤领域
科学探索的世界充满挑战,AtaGenix致敬每一位拓荒者,更致力于成为您信赖的合作伙伴!